Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.30 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952208 | 0.97 | — | — | |
| SCHEMBL8731771 | 0.86 | CA2 (0.42) | CA2CA9HIF1AALDH1A1TP53 | |
| SCHEMBL13284809 | 0.86 | CA2 (0.42) | CA2CA9HIF1AALDH1A1TP53 | |
| SCHEMBL17052578 | 0.86 | CA2 (0.42) | CA2CA9HIF1AALDH1A1TP53 | |
| SCHEMBL23130636 | 0.86 | HIF1A (0.41) | HIF1AALDH1A1TP53TSHRHSD17B10 | |
| SCHEMBL17613231 | 0.86 | HIF1A (0.41) | HIF1AALDH1A1TP53TSHRHSD17B10 | |
| SCHEMBL11990606 | 0.86 | HIF1A (0.41) | HIF1AALDH1A1TP53TSHRHSD17B10 | |
| SCHEMBL17613220 | 0.86 | HIF1A (0.41) | HIF1AALDH1A1TP53TSHRHSD17B10 | |
| SCHEMBL18768831 | 0.86 | HIF1A (0.41) | HIF1AALDH1A1TP53TSHRHSD17B10 | |
| SCHEMBL3955608 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285576-A1 | TREATMENT OF CANCER USING A CYCLODEXTRIN-CONTAINING POLYMER-TOPOISOMERASE INHIBITOR CONJUGATE AND A PARP INHIBITOR | ELLIPSES PHARMA LTD (GB) | 2023-09-14 | — | — | US | disclosed |
| US-9598503-B2 | Methods and systems for polymer precipitation and generation of particles | CERULEAN PHARMA INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160166567-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160101185-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140213504-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | CERULEAN PHARMA INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140105891-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130096293-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120114658-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2012-05-10 | — | — | US | disclosed |
| US-20110152512-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285576-A1 | TREATMENT OF CANCER USING A CYCLODEXTRIN-CONTAINING POLYMER-TOPOISOMERASE INHIBITOR CONJUGATE AND A PARP INHIBITOR | PARP1, TOP1, PARP2 | CA2 1733/4885CA9 220/4885HIF1A 921/4885 |
| US-20120114658-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | CA2 3075/4885CA9 731/4885HIF1A 2942/4885 |
| US-20130096293-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, STT3B, STT3A | CA2 2630/4885CA9 1186/4885HIF1A 2249/4885 |
| US-20160101185-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | CA2 3075/4885CA9 731/4885HIF1A 2942/4885 |
| US-20140213504-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | IAPP, PRCP, DDOST | CA2 3029/4885CA9 1283/4885HIF1A 4206/4885 |
| US-20160166567-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | CA2 3075/4885CA9 731/4885HIF1A 2942/4885 |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | CA2 2610/4885CA9 1455/4885HIF1A 4431/4885 |
| US-20140105891-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | CA2 3075/4885CA9 731/4885HIF1A 2942/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | CA2 2610/4885CA9 1455/4885HIF1A 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.